Obstet Gynecol Sci.  2020 Jan;63(1):87-93. 10.5468/ogs.2020.63.1.87.

Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome

• Saljoughi
• Nasri K
• Bayani M

• KMID: 2467936
• DOI: http://doi.org/10.5468/ogs.2020.63.1.87

Abstract

OBJECTIVE
Recently, the association between periodontal diseases and polycystic ovary syndrome (PCOS) has been established, and it has been revealed that visfatin levels increase in chronic periodontitis (CP) and PCOS. However, there was no study comparing the mean visfatin levels between advanced CP and PCOS. Therefore, the probable role of visfatin linking these diseases remains unknown, and this study was conducted to address this gap.
METHODS
In this age- and weight-matched case-control study (cases with PCOS disease and controls without it), 110 female participants were divided into 4 groups based on clinical findings. The 1st group participants had both PCOS and advanced CP (n=30), 2nd group participants had only PCOS (n=25), 3rd group participants had only advanced CP (n=23), and 4th group comprised of healthy participants (n=32). Enzyme-linked immunosorbent assay was used to investigate visfatin levels in the gingival crevicular fluid (GCF). Data were collected and analyzed using Stata software (version 11).
RESULTS
The results revealed the significant effect of both PCOS and advanced CP on visfatin levels in the GCF (P < 0.05).
CONCLUSION
According to the results of this study, the visfatin level in the GCF could be the probable link of association between PCOS and advanced CP.

Keyword

Visfatin; Polycystic ovary syndrome; Periodontal disease

MeSH Terms

Case-Control Studies
Chronic Periodontitis*
Enzyme-Linked Immunosorbent Assay
Female
Gingival Crevicular Fluid*
Healthy Volunteers
Humans
Nicotinamide Phosphoribosyltransferase*
Periodontal Diseases
Polycystic Ovary Syndrome*
Nicotinamide Phosphoribosyltransferase

Reference

1. Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J. Circulating serum level of visfatin in patients with endometrial cancer. Biomed Res Int. 2018; 2018:8576179. PMID: 29516012.

2. Wang WD, Xing L, Teng JR, Li S, Mi NA. Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes. Exp Ther Med. 2015; 9:2219–2224. PMID: 26136963.

3. Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci. 2012; 8:214–218. PMID: 22661992.

4. Wilder RS, Moretti AJ. Gingivitis and periodontitis in adults: classification and dental treatment [Internet]. Wellesley (MA): UpToDate;c2010. cited 2019 Oct 16. Available from: http://www.uptodatecomlpatients/content/topicdo.

5. Cardoso EM, Reis C, Manzanares-Céspedes MC. Chronic periodontitis, inflammatory cytokines, and interrelationship with other chronic diseases. Postgrad Med. 2018; 130:98–104. PMID: 29065749.

6. Akcalı A, Bostanci N, Özçaka Ö, Öztürk-Ceyhan B, Gümüş P, Tervahartiala T, et al. Elevated matrix metalloproteinase-8 in saliva and serum in polycystic ovary syndrome and association with gingival inflammation. Innate Immun. 2015; 21:619–625. PMID: 25712810.

7. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019; 92:108–120. PMID: 30445140.

8. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf). 1994; 41:473–481. PMID: 7955458.

9. Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017; 37:1036–1047. PMID: 28657375.

10. Dursun E, Akalın FA, Güncü GN, Çınar N, Aksoy DY, Tözüm TF, et al. Periodontal disease in polycystic ovary syndrome. Fertil Steril. 2011; 95:320–323. PMID: 20800834.

11. Kellesarian SV, Malignaggi VR, Kellesarian TV, Al-Kheraif AA, Alwageet MM, Malmstrom H, et al. Association between periodontal disease and polycystic ovary syndrome: a systematic review. Int J Impot Res. 2017; 29:89–95. PMID: 28275229.

12. Tanguturi SC, Nagarakanti S. Polycystic ovary syndrome and periodontal disease: underlying links- a review. Indian J Endocrinol Metab. 2018; 22:267–273. PMID: 29911043.

13. D'Aiuto F, Sabbah W, Netuveli G, Donos N, Hingorani AD, Deanfield J, et al. Association of the metabolic syndrome with severe periodontitis in a large U.S. population-based survey. J Clin Endocrinol Metab. 2008; 93:3989–3994. PMID: 18682518.

14. Bullon P, Morillo JM, Ramirez-Tortosa MC, Quiles JL, Newman HN, Battino M. Metabolic syndrome and periodontitis: is oxidative stress a common link? J Dent Res. 2009; 88:503–518. PMID: 19587154.

15. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003; 24:302–312. PMID: 12788801.

16. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002; 77:1095–1105. PMID: 12057712.

17. Kim JJ, Choi YM, Hong MA, Kim MJ, Chae SJ, Kim SM, et al. Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls. Obstet Gynecol Sci. 2018; 61:253–260. PMID: 29564317.

18. Bayani M, Pourali M, Keivan M. Possible interaction between visfatin, periodontal infection, and other systemic diseases: a brief review of literature. Eur J Dent. 2017; 11:407–410. PMID: 28932156.

19. Hognogi LD, Simiti LV. The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016; 89:322–326.

20. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999; 4:1–6. PMID: 10863370.

21. Rahiminejad ME, Moaddab A, Zaryoun H, Rabiee S, Moaddab A, Khodadoustan A. Comparison of prevalence of periodontal disease in women with polycystic ovary syndrome and healthy controls. Dent Res J (Isfahan). 2015; 12:507–512. PMID: 26759585.

22. Varadan M, Gopalkrishna P, Bhat PV, Kamath SU, S K, K TG, et al. Influence of polycystic ovary syndrome on the periodontal health of Indian women visiting a secondary health care centre. Clin Oral Investig. 2019; 23:3249–3255.

23. Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, Sharma A. Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. J Periodontol. 2011; 82:1314–1319. PMID: 21309715.

24. Pradeep AR, Raghavendra NM, Sharma A, Patel SP, Raju A, Kathariya R, et al. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. J Periodontol. 2012; 83:629–634. PMID: 21966944.

25. Gümüş Ü, Güzel AI, Topcu HO, Timur H, Yılmaz N, Danışman N. Plasma visfatin levels in adolescents with polycystic ovary syndrome: a prospective case-control study. J Pediatr Adolesc Gynecol. 2015; 28:249–253. PMID: 26049941.

26. Dıkmen E, Tarkun I, Cantürk Z, Cetınarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol. 2011; 27:475–479. PMID: 20586547.

27. Bannigida DM, Nayak SB, R V. Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome. Arch Physiol Biochem. 2018; 1–4.

28. Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25:536–542. PMID: 19533482.

29. Sun Y, Wu Z, Wei L, Liu C, Zhu S, Tang S. High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. Gynecol Endocrinol. 2015; 31:808–814. PMID: 26422683.

30. Tabari ZA, Keshani F, Sharbatdaran M, Banishahabadi A, Nejatifard M, Ghorbani H. Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: an immunohistochemical analysis. Dent Res J (Isfahan). 2018; 15:104–110. PMID: 29576773.